Related Experiment Videos
Sensitivity of cultured human osteosarcoma and chondrosarcoma cells to retinoic acid
Abstract:
The ability of retinoic acid (RA) to inhibit the growth of three cell lines (Te85, Hs781, and Hs791) derived from human osteosarcomas and two cell lines (Hs705 and Hs819) derived from human chondrosarcomas was studied in culture. The exposure to 10(-5) M RA resulted, within 4 days, in changes in both cell morphology and cell growth. RA-treated cells appeared flat and spread on the substratum more than untreated cells, their exponential growth rates decreased, and their saturation densities were markedly reduced. All these effects could be reversed by removal of RA from the growth medium. The various cell lines exhibited differential susceptibility to the growth-inhibitory effect of RA. The most sensitive was the Hs705 chondrosarcoma. The proliferation of these cells was inhibited 50% by 10(-9) M RA and was completely blocked by 10(-5) m RA. In contrast, the concentrations of RA required for 50% inhibition of Hs791, Te85, Hs819, and Hs781 were 10(-7), 2 X 10(-7), 2.5 X 10(-7), and 2 X 10(-6) M, respectively. Only the Te85 and the Hs781 osteosarcoma cells and cells derived from a chondrosarcoma biopsy were able to form colonies in a semisolid medium, and this growth was dramatically inhibited by RA. These results demonstrate that RA can suppress in these mesenchymal tumor cells the expression of morphological and growth properties frequently associated with transformed cells.
Insights
Retinoic acid (RA) inhibits the growth and alters the morphology of human osteosarcoma and chondrosarcoma cells in culture. These effects are reversible and vary by cell line, demonstrating RA
Area of Science:
- Molecular Biology
- Cancer Research
- Cell Biology
Background:
- Mesenchymal tumors, including osteosarcomas and chondrosarcomas, represent significant challenges in oncology.
- Understanding the molecular mechanisms that regulate the growth and differentiation of these tumor cells is crucial for developing novel therapeutic strategies.
- Retinoic acid (RA), a derivative of vitamin A, is known to influence cell growth, differentiation, and morphology in various cell types.
Purpose of the Study:
- To investigate the inhibitory effects of retinoic acid (RA) on the growth and morphology of human osteosarcoma and chondrosarcoma cell lines in vitro.
- To determine the differential susceptibility of various human bone tumor cell lines to RA-induced growth inhibition.
- To assess the impact of RA on anchorage-independent growth (colony formation) in a semisolid medium.
Main Methods:
- Culturing of five human bone tumor cell lines: three osteosarcoma (Te85, Hs781, Hs791) and two chondrosarcoma (Hs705, Hs819).
- Treatment of cell cultures with varying concentrations of retinoic acid (RA), including 10(-5) M, and assessment of morphological changes and growth rates over 4 days.
- Evaluation of RA's effect on colony formation in semisolid medium for cell lines capable of anchorage-independent growth.
Main Results:
- Retinoic acid (RA) exposure at 10(-5) M altered cell morphology, causing cells to appear flatter and more spread, and significantly reduced exponential growth rates and saturation densities.
- All observed effects of RA were reversible upon its removal from the growth medium.
- Differential sensitivity to RA's growth-inhibitory effects was observed, with the Hs705 chondrosarcoma cell line being the most sensitive (50% inhibition at 10(-9) M RA). Colony formation in semisolid medium was dramatically inhibited by RA in osteosarcoma and chondrosarcoma cells.
Conclusions:
- Retinoic acid (RA) demonstrates potent inhibitory effects on the proliferation and morphological characteristics of human osteosarcoma and chondrosarcoma cells in vitro.
- The study highlights the differential sensitivity of mesenchymal tumor cells to RA, suggesting potential for targeted therapeutic applications.
- RA suppresses the expression of morphological and growth properties associated with transformed cells, indicating its potential as an anti-cancer agent for bone tumors.